Ocugen (OCGN) Expected to Announce Earnings on Wednesday

Ocugen (NASDAQ:OCGN) is anticipated to release its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect Ocugen to post earnings of ($0.06) per share and revenue of $0.86 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 8:30 AM ET.

Ocugen Stock Performance

Shares of OCGN opened at $1.82 on Monday. Ocugen has a one year low of $0.52 and a one year high of $1.96. The company has a market cap of $568.42 million, a PE ratio of -8.27 and a beta of 2.75. The stock has a 50-day moving average of $1.54 and a 200-day moving average of $1.40. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.85 and a quick ratio of 1.85.

Institutional Investors Weigh In On Ocugen

Several institutional investors and hedge funds have recently added to or reduced their stakes in OCGN. SmartHarvest Portfolios LLC bought a new position in shares of Ocugen during the 4th quarter worth approximately $31,000. NewEdge Advisors LLC increased its position in shares of Ocugen by 198.0% during the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock valued at $36,000 after acquiring an additional 24,460 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Ocugen by 56.7% during the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock worth $36,000 after acquiring an additional 13,326 shares during the period. Schonfeld Strategic Advisors LLC bought a new stake in Ocugen during the fourth quarter worth $38,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in Ocugen by 28,222.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company’s stock worth $41,000 after purchasing an additional 30,198 shares during the last quarter. Hedge funds and other institutional investors own 10.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on OCGN shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Chardan Capital reiterated a “buy” rating and issued a $7.00 target price on shares of Ocugen in a report on Tuesday, January 20th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ocugen has an average rating of “Hold” and a consensus price target of $7.00.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.